Novacyt Completes Acquisition of Southern Cross Diagnostics

The latest announcement is out from Novacyt ( (FR:ALNOV) ).

Novacyt S.A., a France-headquartered molecular diagnostics specialist listed in Paris and London, provides integrated genomic medicine technologies across clinical diagnostics, instrumentation and research-use-only services. Its portfolio spans reproductive health, precision medicine, infectious disease testing, DNA sample preparation platforms and qPCR instruments, serving customers in over 65 countries.

The company has completed the acquisition of Southern Cross Diagnostics Pty Ltd through its wholly owned subsidiary Novacyt Holdings UK Limited, following an earlier notification in February 2026. Novacyt said it will provide further details of a planned Preferential Subscription Rights issue immediately after this announcement, signalling additional financing activity linked to its expansion strategy.

More about Novacyt

Novacyt S.A. is an international molecular diagnostics company focused on genomic medicine, developing, manufacturing and commercialising molecular assays and instruments. It serves human health, animal health and environmental sectors through three segments: clinical in vitro diagnostics, DNA sample preparation and PCR instrumentation, and research-use-only services including high-performance qPCR assays and genomic sequencing support. The group is headquartered in Le Vésinet, France, with offices in the U.K., Singapore, the U.S. and Canada, and a commercial presence in more than 65 countries, and its shares trade on Euronext Growth Paris and London’s AIM market.

See more data about ALNOV stock on TipRanks’ Stock Analysis page.